Novo Holdings to help young Danish company with efforts to provide scale to start-ups
A Danish bio industrial scale-up company has landed an $86 million investment from Novo Holdings, and it’s hoping to build on a technology base from Novozymes. And with that investment will come a new manufacturing site.
21st.BIO was founded in 2020, and is focused on supporting the upscaling of companies across the world, with the intention of helping those companies meet market demand. Its focus are peptides and proteins, and it wants to provide startups access to facilities to develop a molecule production process that can deliver a high-quality product in the most cost-effective way.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.